Mimura S, Narahara H, Uehara H, Otani T, Okuda S
Dept. of Gastroenterology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
Gan To Kagaku Ryoho. 1996 Jan;23(1):41-6.
In this article, we first present our clinical data on PDT for the treatment of gastric cancer and make a comparison between a continuous wave laser and a pulsed laser. The reasons for PDT failure in certain cases are also discussed. In the fifteen years from 1981 to 1995, we have treated a total of 76 gastric cancer lesions (73 cases), which was consist of 69 early gastric cancer lesions (66 cases) and seven advanced gastric cancer lesions (seven cases) by PDT. From 1981 to 1990, we used an argon dye laser (ADL, Models 171-08 and 375-03, Spectra-Physics, Mountain View, Calif., US) as an excitation light source for PDT with HpD (Photofrin I), DHE (Photofrin II) or PHE (freeze-dried Photofrin II). From analysis of the results in terms of the depth of cancer invasion in these 44 lesions (41 cases), the rate of cure for mucosal carcinomas was 57% (13/23), that of submucosal carcinomas was 53% (10/19), and that of carcinomas invading more than the muscularis propria was 0% (0/2). These data can be interpreted to indicate that the ADL laser beam could not penetrate and supply sufficient energy to activate HpD not only in the submoucosal layer but also in the mucosal layer. In 1990, therefore, we investigated an excimer dye laser (EDL, Hamamatsu Photonics, Hamamatsu, Japan), because its pulsed beam with extremely high peak power was expected to be more efficient at exciting HpD than continuous wave lasers such as ADL and high frequency pulsed lasers such as cooper vapor dye laser (Cu VDL). From 1990 to 1995, twenty-seven early gastric cancer lesions (27 cases) and five advanced gastric cancer lesions (five cases) were treated by PDT with EDL and PHE. Of these 32 lesions, the rate of cure for mucosal carcinomas was 100% (15/15), that of submucosal carcinomas was 75% (9/12), and that of carcinomas invading more than the muscularis propria was 20% (1/5). For the purpose of determining how much energy was required for a complete cure in early gastric cancer, and to compare the efficacy of ADL and EDL, the relation between the response (cure or no cure) and irradiated energy intensity (dose: J/cm 2) was evaluated by the depth of cancer invasion and kind of laser used in PDT. A smaller EDL dose was more effective than ADL in terms of photodynamic action.
在本文中,我们首先展示了光动力疗法(PDT)治疗胃癌的临床数据,并对连续波激光和脉冲激光进行了比较。我们还讨论了某些情况下PDT治疗失败的原因。在1981年至1995年的15年间,我们共对76个胃癌病灶(73例患者)进行了PDT治疗,其中包括69个早期胃癌病灶(66例患者)和7个进展期胃癌病灶(7例患者)。1981年至1990年,我们使用氩离子染料激光(ADL,型号171 - 08和375 - 03,美国加利福尼亚州山景城光谱物理公司)作为激发光源,联合血卟啉衍生物(HpD,Photofrin I)、二血卟啉醚(DHE,Photofrin II)或冻干血卟啉醚(PHE,freeze - dried Photofrin II)进行PDT治疗。通过对这44个病灶(41例患者)的癌症浸润深度分析结果显示,黏膜癌的治愈率为57%(13/23),黏膜下癌的治愈率为53%(10/19),而浸润超过固有肌层的癌症治愈率为0%(0/2)。这些数据表明ADL激光束不仅无法穿透黏膜下层,也无法穿透黏膜层并提供足够能量来激活HpD。因此,在1990年,我们研究了准分子染料激光(EDL,日本滨松光子学公司),因为其具有极高峰值功率的脉冲光束预计比连续波激光如ADL以及高频脉冲激光如铜蒸气染料激光(Cu VDL)在激发HpD方面更有效。1990年至1995年,我们使用EDL联合PHE对27个早期胃癌病灶(27例患者)和5个进展期胃癌病灶(5例患者)进行了PDT治疗。在这32个病灶中,黏膜癌的治愈率为100%(15/15),黏膜下癌的治愈率为75%(9/12),浸润超过固有肌层的癌症治愈率为20%(1/5)。为了确定早期胃癌完全治愈所需的能量,并比较ADL和EDL的疗效,我们根据PDT中癌症浸润深度和使用的激光类型评估了反应(治愈或未治愈)与照射能量强度(剂量:J/cm²)之间的关系。就光动力作用而言,较小的EDL剂量比ADL更有效。